Mabion adds $10M to Twiti loan line, doubling available financing
What's the deal? Polish biotech MabionDealroom has a profile for this one. Try Dealroom → has expanded its loan agreement with Twiti InvestmentsDealroom has a profile for this one. Try Dealroom → by an additional 10 million złoty (roughly $10 million), the company disclosed on September 1, 2026. The annex raises Twiti's loan line from 18 million złoty and gives Mabion access to funds through December 31, 2028.
Why now? Mabion had already drawn two tranches totalling 10 million złoty from the original 18 million złoty facility, signed in October 2025. With the new tranche, 18 million złoty now remains available to the company.
The terms: Each drawdown must be repaid within two years of its disbursement. Mabion will establish repayment security before funds are released, at Twiti's request and on its timeline.
Why it matters? This is a quick re-raise from the same backer. Just weeks earlier, in late August 2026, Mabion moved to convert part of its existing debt to Twiti into new series W shares, folding the lender deeper into its capital structure.
What the company said? Expanding the line "demonstrates the partner's trust in the company and its development strategy," Mabion stated, citing Twiti's willingness to provide "long-term support" (translated from Polish).
The signal: Repeat financing from a single committed lender — paired with debt-to-equity conversion — points to a scaleup leaning on a strategic partner rather than broad capital markets. For a listed biotech, keeping one backer close can secure runway, but it also concentrates risk in one relationship.
Read more: bankier.pl
Image credit: Generated with Gemini
